Bavarian Nordic A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVNRY research report →
About the company
Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypox (known as IMVAMUNE, IMVANEX, and JYNNEOS), as well as human rabies protection (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), and an Ebola vaccine (MVABEA). The company also boasts a robust pipeline of investigational therapies.
- CEO
- Paul John Chaplin
- IPO
- 2013
- Employees
- 1,645
- HQ
- Hellerup, DK
Price Chart
- Market Cap
- $2.22B
- P/E
- 12.52
- P/S
- 2.48
- P/B
- 1.16
- EV/EBITDA
- 6.29
- Div Yield
- 0.00%
- Gross Margin
- 47.40%
- Op Margin
- 25.36%
- Net Margin
- 19.83%
- ROE
- 9.25%
- ROIC
- 8.35%
- Revenue
- $5.93B · 3.81%
- Net Income
- $1.32B · 33.87%
- EPS
- $5.66 · 34.66%
- Op Income
- $885.42M
- FCF YoY
- 822.97%
- 52W High
- $13.00
- 52W Low
- $8.67
- 50D MA
- $9.60
- 200D MA
- $10.26
- Beta
- 0.96
- Avg Volume
- 4.20K
Get TickerSpark's AI analysis on BVNRY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BVNRY coverage
Recent articles, reports, and earnings notes.
No research on BVNRY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BVNRY report →Similar companies
Peers in the same neighborhood.